Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
TENAX THERAPEUTICS, INC. (TENX)
|
Add to portfolio |
|
|
|
| Price: |
$2.01
| | Metrics |
| OS: |
23.9
|
M
| |
|
|
| Market cap: |
$48
|
M
| |
|
|
|
Net cash:
|
$13
|
M
| |
$0.55
|
per share
|
|
EV:
|
$34.9
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$11.7
|
M
| |
3.0
|
x EV/EBITDA
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Apr-30-15 | Apr-30-14 |
| Revenues | 65.5 | 19.7 | 17.1 | 13.8 | 18.4 | 105.3 | 0.0 | 0.2 |
| Revenue growth | 231.7% | 15.3% | 24.1% | -25.1% | -82.5% | | -69.0% | -86.7% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -29.6 | 0.1 |
| Gross profit | 65.5 | 19.7 | 17.1 | 13.8 | 18.4 | 105.3 | 29.7 | 0.0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 60225.6% | 18.3% |
| Selling, general and administrative | 7.6 | 5.3 | 5.1 | 5.7 | 5.7 | 6.2 | 7.2 | 13.8 |
| Research and development | 25.1 | 4.6 | 3.5 | 1.2 | 3.5 | 13.1 | 6.7 | 3.0 |
| EBITA | 32.7 | 9.9 | 8.6 | 6.9 | 9.2 | 85.9 | 15.9 | 16.7 |
| EBITA margin | 50.0% | 50.0% | 50.0% | 50.0% | 50.0% | 81.6% | 32305.1% | 10491.2% |
| Amortization of intangibles | | | | | | | 0.1 | 0.1 |
| EBIT | 32.7 | 9.9 | 8.6 | 6.9 | 9.2 | 85.9 | 15.9 | 16.6 |
| EBIT margin | 50.0% | 50.0% | 50.0% | 50.0% | 50.0% | 81.6% | 32162.5% | 10452.1% |
| Pre-tax income | -32.5 | -9.9 | 8.4 | 14.1 | 8.8 | 36.0 | 14.1 | 19.5 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -8.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | | 0.0% | 0.0% |
| Net income | -32.5 | -9.9 | 8.4 | 14.1 | 8.8 | 43.9 | 14.1 | 25.3 |
| Net margin | -49.6% | -49.9% | 49.1% | 102.6% | 48.0% | 41.7% | 28571.6% | 15947.8% |
| |
| Diluted EPS | ($1.58) | ($0.95) | $1.35 | $9.04 | $6.27 | $31.24 | $0.50 | $2.71 |
| Shares outstanding (diluted) | 20.6 | 10.4 | 6.2 | 1.6 | 1.4 | 1.4 | 28.1 | 9.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|